Return to Provider News

Velcade® is the Preferred Therapy over Kyprolis® for certain indications

Audience: Oncologists and Hematologists

We want to make you aware of an upcoming change to the prior authorization criteria for Kyprolis®. This policy change was reviewed and approved by our Pharmacy & Therapeutics Committee, which includes local physicians and pharmacists who are not employed by our Health Plan.

As of September 1, 2021, Velcade® is the preferred drug therapy over Kyprolis for the treatment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma and as primary therapy for multiple myeloma (transplant and non-transplant candidates).

This change will impact new starts only and does not apply to members currently prescribed Kyprolis. This change applies to all lines of business.

Preferred therapy Velcade does not require Prior Authorization.

If submitting a prior authorization request for Kyprolis, please include all of the following relevant clinical information:

  • Diagnosis
  • Clinical justification as to why Velcade is not the best choice for your patient

You may also request an exception to the step-therapy requirement through our step-therapy exception process.

Related News
UPDATE – Preauthorization Requirements for Select Cardiology Services

Colorectal Screening Claim Submission for Commercial Business Line

Preauthorization Updates Effective October 1, 2022, for All Lines of Business Requiring Preauthorization

Updated NDC/HCPCS Codes When Billing for Depo-Provera® (Medroxyprogesterone)

Preauthorization Updates Effective May 1, 2022 for All Lines of Business Requiring Preauthorization

Category

Excellus

News

Pharmacy

Clinical Editing

Utilization Management

IE Browser Modal